Literature DB >> 10612018

Piroxicam encapsulated in liposomes: characterization and in vivo evaluation of topical anti-inflammatory effect.

G S Canto1, S L Dalmora, A G Oliveira.   

Abstract

Liposomes of soya phosphatidylcholine, cholesterol, and stearylamine (molar ratio 6/3/1) and 0.1% alpha-tocopherol were prepared by the extrusion of multilamellar vesicles through 0.2-micron polycarbonate membrane. Liposomes were characterized by electron transmission microscopy, and the mean structure diameter was 278 nm. The encapsulation efficiency obtained was 12.73%. The topical anti-inflammatory effect was evaluated in vivo by the cotton pellet granuloma method. We analyzed free piroxicam at 4 mg/kg, piroxicam encapsulated in liposomes added to 1.5% hydroxyethylcellulose (HEC) gel at 1.6 mg/kg, and piroxicam encapsulated in liposomes added to HEC gel at 4 mg/kg; the inhibition of inflammation obtained was 21.1%, 32.8%, and 47.4%, respectively. These results showed that the encapsulation of piroxicam produced an increase of topical anti-inflammatory effect, suggesting that the inhibition of inflammation can be obtained with lower drug concentrations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10612018     DOI: 10.1081/ddc-100102293

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  3 in total

1.  Effect of surfactants and solutes (glucose and NaCl) on solubility of Kavain--a technical note.

Authors:  Anna Rita Bilia; Luca Scalise; Maria Camilla Bergonzi; Francesco Vincieri
Journal:  AAPS PharmSciTech       Date:  2008-03-08       Impact factor: 3.246

2.  NANOSCALE SELF-ASSEMBLY FOR DELIVERY OF THERAPEUTICS AND IMAGING AGENTS.

Authors:  Mingnan Chen; Jonathan R McDaniel; J Andrew Mackay; Ashutosh Chilkoti
Journal:  Technol Innov       Date:  2011-01-01

Review 3.  Biomaterial-engineered intra-articular drug delivery systems for osteoarthritis therapy.

Authors:  Longfa Kou; Shuyi Xiao; Rui Sun; Shihui Bao; Qing Yao; Ruijie Chen
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.